Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, Two-Part, Multicenter, Non-randomized, Open-label, Multiple Dose First-In-Human Study of DS-8201A, in Subjects With Advanced Solid Malignant Tumors

NCT02564900 is registered in ClinicalTrials.gov with Daiichi Sankyo Co., Ltd. as lead sponsor.

NCT NCT02564900
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02564900 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, Two-Part, Multicenter, Non-randomized, Open-label, Multiple Dose First-In-Human Study of DS-8201A, in Subjects With Advanced Solid Malignant Tumors
Lead sponsor
Daiichi Sankyo Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
September 1, 2015
Completion date
December 22, 2023
Enrollment
292 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors